ABEO - CIK 0000318306
The table below shows ABEONA THERAPEUTICS INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$76.33M | -$56.02M | -$37.01M | -$43.48M | -$65.67M | -$35.02M |
| Capital expenditure | $7.97M | $2.45M | $331.00K | $130.00K | $4.15M | $1.34M |
| Investing cash flow | $105.03M | -$39.24M | $208.00K | -$23.96M | $66.06M | -$83.71M |
| Dividends paid | - | - | - | - | - |
ABEONA THERAPEUTICS INC. reported operating cash flow of -$76.33M for fiscal year 2025. That is down 36.3% from -$56.02M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$13.01M (FY 2016) to -$76.33M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $26.04M | $104.14M | $37.06M | $43.17M | $24.86M | $1.94M |